A slim majority of Americans would consider a pneumococcal vaccine
Core finding
In a Verasight survey of 1,000 U.S. adults conducted Nov. 19 to 22, 2024, 53% of Americans said they are at least somewhat likely to consider receiving a pneumococcal disease vaccine if eligible. This includes 34% who said very likely, with another 20% who said somewhat likely.
About a quarter said they are unlikely to consider it (24%), with 15% who said very unlikely and 9% who said somewhat unlikely. Another 23% were neutral.
Topline scale
53% of Americans are at least somewhat likely to consider a pneumococcal vaccine if eligible.
How likely are you to consider receiving a Streptococcus Pneumoniae (Pneumococcal disease) vaccine if you are eligible?
n = 1,000 · Nov 19–22, 2024 · MoE ±3.4%
Methodology
Full methodology →| Mode | Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting |
|---|---|
| Population | United States adults |
| Field dates | Nov 19–22, 2024 |
| Base (unweighted) | 1,000 |
| Margin of error | ±3.4% |
| Module | A |
| Sponsor | Verasight |
| Weight variable | weight |
| Weighting targets | age, race/ethnicity, sex, income, education, region, metropolitan status |
Sources
- verasight-apha-2024.tiiny.co
How likely are you to consider receiving a Streptococcus Pneumoniae (Pneumococcal disease) vaccine if you are eligible?
Cite this question
Verasight APHA Omnibus Survey #2024-122, fielded November 19-22, 2024, N=1,000 United States adults, +/- 3.4%.